NCT02096666 is a Phase 1, PHASE2 clinical trial of AMG 337 in Stomach Neoplasms, sponsored by Amgen.

Who is sponsoring NCT02096666?

NCT02096666 is sponsored by Amgen.

What drugs are being tested in NCT02096666?

Interventions in NCT02096666: AMG 337.

What condition does NCT02096666 study?

NCT02096666 studies Stomach Neoplasms.

Is NCT02096666 still recruiting?

NCT02096666 is currently completed. Last updated 28 December 2021.

Last reviewed 2021-12-28 · How we verify

NCT02096666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Completed Phase 1, PHASE2 Last updated 28 December 2021

What this trial tests

Phase 1, PHASE2 trial testing AMG 337 in Stomach Neoplasms in 11 participants. Completed in 7 December 2018.

Timeline

15 April 2014

Primary endpoint
5 November 2015

7 December 2018

Quick facts

Lead sponsor	Amgen
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	15 April 2014
Primary completion	5 November 2015
Estimated completion	7 December 2018
Sites	4 locations across Japan

Drugs / interventions tested

AMG 337

Conditions studied

Stomach Neoplasms — all drugs for Stomach Neoplasms →

Sponsor

Amgen — full company profile →

Who can join

20 and older, any sex, with Stomach Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, Phase 1/2 study. The study will evaluate the tolerability, safety and activity of AMG 337 in Asian subjects who have advanced solid tumors (Phase 1) or subjects with MET amplified tumors with a focus on gastric/gastroesophageal junction/esophageal adenocarcinoma (Phase 2).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches.
Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. · · 2021 · cited 54× · PMID 33849569 · DOI 10.1186/s12935-021-01924-w
Targeted therapy in gastroesophageal cancers: past, present and future.
Woo J, Cohen SA, Grim JE. · · 2015 · cited 18× · PMID 26510453 · DOI 10.1093/gastro/gov052
HGF/c-Met Axis: The Advanced Development in Digestive System Cancer.
Shao Z, Pan H, Tu S, Zhang J, et al · · 2020 · cited 14× · PMID 33195182 · DOI 10.3389/fcell.2020.00801
How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C, Mulder K, Spratlin J. · · 2014 · cited 14× · PMID 25142842 · DOI 10.1634/theoncologist.2014-0006
Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.
Matsuoka T, Yashiro M. · · 2021 · cited 7× · PMID 34040699 · DOI 10.4251/wjgo.v13.i5.366

Verify or expand the search:

Other trials of AMG 337

Trials testing the same drug.

NCT03132155 — QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma · Phase 2 · terminated
NCT03147976 — QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors · Phase 2 · withdrawn
NCT01253707 — A Study of AMG 337 in Subjects With Advanced Solid Tumors · Phase 1 · completed

Other recruiting trials for Stomach Neoplasms

Currently open trials in the same condition.

NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT07504913 — Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 · recruiting
NCT07113340 — Carina™ Surgical Platform for Minimal Radical Gastrectomy · NA · active not recruiting
NCT06630130 — Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer · Phase 2 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02096666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 28 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02096666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing